| Literature DB >> 28515335 |
Maxim Bez1,2, Dmitriy Sheyn2,3, Wafa Tawackoli2,3,4,5, Pablo Avalos3, Galina Shapiro1, Joseph C Giaconi6, Xiaoyu Da4, Shiran Ben David2,3, Jayne Gavrity7, Hani A Awad7, Hyun W Bae2, Eric J Ley2, Thomas J Kremen2,8, Zulma Gazit1,2,3,8, Katherine W Ferrara9, Gadi Pelled1,2,3,4,5, Dan Gazit10,2,3,4,5,8.
Abstract
More than 2 million bone-grafting procedures are performed each year using autografts or allografts. However, both options carry disadvantages, and there remains a clear medical need for the development of new therapies for massive bone loss and fracture nonunions. We hypothesized that localized ultrasound-mediated, microbubble-enhanced therapeutic gene delivery to endogenous stem cells would induce efficient bone regeneration and fracture repair. To test this hypothesis, we surgically created a critical-sized bone fracture in the tibiae of Yucatán mini-pigs, a clinically relevant large animal model. A collagen scaffold was implanted in the fracture to facilitate recruitment of endogenous mesenchymal stem/progenitor cells (MSCs) into the fracture site. Two weeks later, transcutaneous ultrasound-mediated reporter gene delivery successfully transfected 40% of cells at the fracture site, and flow cytometry showed that 80% of the transfected cells expressed MSC markers. Human bone morphogenetic protein-6 (BMP-6) plasmid DNA was delivered using ultrasound in the same animal model, leading to transient expression and secretion of BMP-6 localized to the fracture area. Micro-computed tomography and biomechanical analyses showed that ultrasound-mediated BMP-6 gene delivery led to complete radiographic and functional fracture healing in all animals 6 weeks after treatment, whereas nonunion was evident in control animals. Collectively, these findings demonstrate that ultrasound-mediated gene delivery to endogenous mesenchymal progenitor cells can effectively treat nonhealing bone fractures in large animals, thereby addressing a major orthopedic unmet need and offering new possibilities for clinical translation.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28515335 PMCID: PMC5524999 DOI: 10.1126/scitranslmed.aal3128
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956